These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23121271)

  • 1. Early response of ceftaroline fosamic in the treatment of soft-tissue infections.
    Giuliano C; Kale-Pradhan PB; Johnson LB
    Expert Rev Clin Pharmacol; 2012 Sep; 5(5):509-12. PubMed ID: 23121271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summary of ceftaroline fosamil clinical trial studies and clinical safety.
    File TM; Wilcox MH; Stein GE
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S173-80. PubMed ID: 22903949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Jorgenson MR; DePestel DD; Carver PL
    Ann Pharmacother; 2011 Nov; 45(11):1384-98. PubMed ID: 22009993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
    Corey GR; Wilcox MH; Talbot GH; Thye D; Friedland D; Baculik T;
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv41-51. PubMed ID: 21115454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
    Wilcox MH; Corey GR; Talbot GH; Thye D; Friedland D; Baculik T;
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv53-iv65. PubMed ID: 21115455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.
    Friedland HD; O'Neal T; Biek D; Eckburg PB; Rank DR; Llorens L; Smith A; Witherell GW; Laudano JB; Thye D
    Antimicrob Agents Chemother; 2012 May; 56(5):2231-6. PubMed ID: 22314524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.
    Scott LJ
    Drugs; 2016 Nov; 76(17):1659-1674. PubMed ID: 27766567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA.
    Stryjewski ME; Jones RN; Corey GR
    Diagn Microbiol Infect Dis; 2015 Mar; 81(3):183-8. PubMed ID: 25583130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftaroline fosamil for community-acquired pneumonia and skin and skin structure infections: a systematic review.
    El Hajj MS; Turgeon RD; Wilby KJ
    Int J Clin Pharm; 2017 Feb; 39(1):26-32. PubMed ID: 28058593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Poon H; Chang MH; Fung HB
    Clin Ther; 2012 Apr; 34(4):743-65. PubMed ID: 22444785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftaroline fosamil for treating skin and skin structure infections or community-acquired pneumonia in patients with renal insufficiency.
    Maggiore C; Pasquale T; Cole P; Friedland HD
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):141-53. PubMed ID: 25467425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of ceftaroline in treating complicated skin and soft tissue infections].
    Eckmann C
    Dtsch Med Wochenschr; 2014 Nov; 139 Suppl 3():S87-8. PubMed ID: 25429538
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials.
    Shorr AF; Kollef M; Eckburg PB; Llorens L; Friedland HD
    Diagn Microbiol Infect Dis; 2013 Mar; 75(3):298-303. PubMed ID: 23357290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftaroline fosamil use in hospitalized patients with acute bacterial skin and skin structure infections: Budget impact analysis from a hospital perspective.
    Huang X; Beresford E; Lodise T; Friedland HD
    Am J Health Syst Pharm; 2013 Jun; 70(12):1057-64. PubMed ID: 23719884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftaroline: a comprehensive update.
    Kaushik D; Rathi S; Jain A
    Int J Antimicrob Agents; 2011 May; 37(5):389-95. PubMed ID: 21420284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ceftaroline fosamil for bacteremia associated with community-acquired bacterial pneumonia.
    Jandourek A; Smith A; Llorens L; Thye DA; Eckburg PB; Friedland HD
    Hosp Pract (1995); 2014 Feb; 42(1):75-8. PubMed ID: 24566599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftaroline fosamil: a new broad-spectrum cephalosporin.
    Laudano JB
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii11-8. PubMed ID: 21482565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections in obese patients.
    Evans JD; Udeani G; Cole P; Friedland HD
    Postgrad Med; 2014 Sep; 126(5):128-34. PubMed ID: 25295657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections.
    Beresford E; Biek D; Jandourek A; Mawal Y; Riccobene T; Friedland HD
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):123-35. PubMed ID: 24494793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftaroline fosamil: just another intravenous antibiotic.
    Prescrire Int; 2013 Dec; 22(144):291. PubMed ID: 24600728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.